Latest updates and industry news.
Scailyte and Sanofi Collaboration Solves Critical Manufacturing Challenge for NK Cell Therapy, New Paper Reveals
November 11 2025, Scailyte's AI-driven ScaiVision™ platform successfully identified a predictive biomarker for manufacturing success where standard analysis methods failed, creating an actionable solution to de-risk cell therapy production.
Scailyte and Visterra Partner to Advance Autoimmune Disease Research
December 17 2024, Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharmaceutical company, today announced a research collaboration with the goal to accelerate the development of innovative treatments for autoimmune diseases.
Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor
July 2 2024, Scailyte Announces Virginia Savova, PhD as a Strategic and Scientific Advisor. Dr. Savova brings strong expertise in computational biology, immunology, and cancer research, with a track record of high-profile publications.
Scailyte Extends Series A to USD 8 Million
December 04 2023, We are thrilled to announce the extension of our Series A funding, bringing the total raised amount to USD 8 million.
Scailyte and MaxiVAX Solve Clinical Challenges with Data-Driven Collaboration
July 05 2023, Scailyte and MaxiVAX, two cutting-edge precision medicine organizations, proudly announce their collaboration to improve patient outcomes.
Scailyte Announces a Collaboration with Turnstone Biologics
March 16 2023, Scailyte Announces Collaboration with Turnstone Biologics to Identify Biomarker Signatures in Solid Tumors with TIL Therapy.
